Abstract 5489
Background
Although neoadjuvant chemoradiotherapy is the standard treatment for locally advanced rectal cancer (LARC), it remains difficult to predict the prognosis of LARC patients. We aimed to explore the impacts of local immune status on survival of LARC after noeadjuvant radiotherapy (nRT).
Methods
A total of 76 consecutive LARC patients were enrolled in our institute from February 2012 to September 2015. CD3+ T-cell and CD8+ T-cell count were determined from surgical specimens. Factors associated with disease-free survival (DFS) and overall survival (OS) were identified by univariate and multivariate Cox regression. SPSS 22.0 was used for statistical analyse.
Results
The median follow-up time was 29.0 months (range 2.0-59). The Cutoff Finder software identified an optimal CD3+ T-cell cutoff value of 12.5% and CD8+ T-cell value of 9% for our patients. According to the Kaplan-Meier analysis, CD3+ T-cell ≥12.5% was significantly related to favorable DFS (P = 0.020), while there was no significant difference between CD3+ T-cell and OS (P = 0.238). Meanwhile, CD8+ T-cell ≥9% was found to have a positive effect on DFS and OS (P = 0.012 and P = 0.035, respectively). In the multivariate Cox regression model, CD8+ T-cell <9% was independent risk factors for poor DFS (HR = 0.492, 95%CI= 0.252-0.960, P = 0.038). Furthermore, CD8+ T-cell (HR = 0.268, 95%CI= 0.076-0.941, P = 0.040) and T stage (HR = 0.151, 95%CI= 0.030-0.7530, P = 0.021) were independent predictors of OS.
Conclusions
High CD8+ T-cell count were significantly related to good survival in LARC patients with nRT. Local immune status was suggested to be measured in order to predict the prognosis of patients with LACR after nRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xijin Lin.
Funding
The Fujian Province Natural Science Foundation (2017J01260), Joint Funds for the Innovation of Science and Technology, Fujian province (2017Y9074), and the Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education/Beijing (2017 Open Project-9).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2786 - Development of a living organoid biobank derived from colorectal cancer patients: towards personalized medicine
Presenter: Federica Papaccio
Session: Poster Display session 2
Resources:
Abstract
3351 - Microsatellite Instability Detection in Colorectal Cancer: 44-Center Comparison between the Idylla MSI Assay and Routine Molecular and Immunohistochemistry Tests on Formalin-Fixed Paraffin-Embedded Tissue
Presenter: Xavier Matias-guiu
Session: Poster Display session 2
Resources:
Abstract
4901 - Expression profile of EPHB3 and its prognostic significance in colorectal cancer progression (Running head: Prognostic value of EPHB3 in colorectal cancers)
Presenter: Bogun Jang
Session: Poster Display session 2
Resources:
Abstract
5030 - A pan-ErbB family inhibitor, AF8c, promotes apoptosis by DR5/Nrf2 activation via ROS in colorectal cancer cells
Presenter: Soyeon Jeong
Session: Poster Display session 2
Resources:
Abstract
5053 - Frequent BRAF, GNAS and SMAD4 mutations identified in Colorectal Mucinous Carcinomas
Presenter: Sun Mi Lee
Session: Poster Display session 2
Resources:
Abstract
5220 - Impact of CCL4 knockout using CRISPR Cas-9 technology on colorectal tumor progression
Presenter: Roba Barakat
Session: Poster Display session 2
Resources:
Abstract
5330 - Independent clinical validation of a gene expression profile to predict benefit of 5-FU in metastatic colorectal cancer
Presenter: Ida Buhl
Session: Poster Display session 2
Resources:
Abstract
5515 - WRN mutated Colorectal Cancer (CRC) is characterized by a distinct molecular and immunological profile
Presenter: Andreas Seeber
Session: Poster Display session 2
Resources:
Abstract
5716 - Mutation analysis of B2M gene in colorectal cancer patients with microsatellite instability
Presenter: Ivana Kašubová
Session: Poster Display session 2
Resources:
Abstract
870 - Selective Wnt/β-catenin small-molecule inhibitor CWP232228 impairs tumor growth of colon cancer
Presenter: Jin Young Kim
Session: Poster Display session 2
Resources:
Abstract